Short Sellers Grow More Selective on Major Biotechs
The September 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
The September 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Gilead, Johnson & Johnson, Potash, Schlumberger, Visa and Walmart.
The top analyst upgrades, downgrades and other research calls from Thursday include CarMax, DowDuPont, Gilead Sciences, GrubHub, Microsoft, Nike and Western Digital.
The top analyst upgrades, downgrades and other research calls from Wednesday include Freeport-McMoran, Gilead Sciences, FuelCell, Oracle, Take-Two Interactive, Tesla and Waste Management.
Thursday was a relatively mixed day for the U.S. broad markets. Although all the major averages started off negative a couple actually turned a gain on the day. Crude oil gave some…
The September 15 short interest data have been compared with the previous report, and short interest in all the selected biotech stocks increased.
The August 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The include Abercrombie & Fitch, Arch Coal, Baker Hughes, BioMarin Pharmaceutical, Gilead Sciences, Hasbro and Snap.
Gilead Sciences shares have been in a holding pattern for a while. Analysts have said that the firm needs to make a move to shake this situation, otherwise this could turn into…
The August 15 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
The July 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
After a wretched 2016, when many of the top biotech companies were hit hard by campaign rhetoric, the industry has roared back to life this year. Here are four big opportunities for…
The July 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Gilead Sciences, Inc. (NASDAQ: GILD) shares basically remained unchanged after the firm announced an approval from the U.S. Food and Drug Administration (FDA). Essentially, the FDA approved Vosevi (sofosbuvir 400 mg/velpatasvir 100…
The June 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.